Incyte/$INCY
1D1W1MYTD1Y5YMAX
Capital at risk
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
- Ticker
- $INCY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,844
- Headquarters
- Wilmington, United States
- Website
- www.incyte.com
Incyte Metrics
BasicAdvanced
$25B
15.89
$7.85
0.77
-
Price and volume
Market cap
$25B
Beta
0.77
52-week high
$132.60
52-week low
$81.09
Average daily volume
1.3M
Financial strength
Current ratio
4.636
Quick ratio
4.062
Long term debt to equity
0.005
Total debt to equity
0.005
Interest coverage (TTM)
792.78%
Profitability
EBITDA (TTM)
1,942.313
Gross margin (TTM)
55.66%
Net profit margin (TTM)
27.71%
Operating margin (TTM)
31.69%
Effective tax rate (TTM)
18.04%
Revenue per employee (TTM)
$2,050,000
Management effectiveness
Return on assets (TTM)
16.82%
Return on equity (TTM)
30.67%
Valuation
Price to earnings (TTM)
15.891
Price to revenue (TTM)
4.249
Price to book
3.95
Price to tangible book (TTM)
4.1
Price to free cash flow (TTM)
13.08
Free cash flow yield (TTM)
7.65%
Free cash flow per share (TTM)
9.538
Growth
Revenue change (TTM)
26.93%
Earnings per share change (TTM)
79.72%
3-year revenue growth (CAGR)
18.32%
10-year revenue growth (CAGR)
19.98%
3-year earnings per share growth (CAGR)
68.82%
10-year earnings per share growth (CAGR)
35.78%
What the Analysts think about Incyte
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Analyst projections of the future price of Incyte stock.
Bulls say / Bears say
Incyte reported second-quarter adjusted EPS of $3.09 beating the $2.10 consensus and revenue of $1.67 billion topping the $1.42 billion estimate, enabling it to raise full-year net sales guidance to $5.13–5.26 billion (Investing.com)
Incyte completed its $1.25 billion acquisition of Vega Therapeutics, adding VGA039—a Phase III monoclonal antibody in development for von Willebrand disease with Breakthrough Therapy, Fast Track and orphan drug designations—bolstering its late-stage hematology pipeline (Reuters)
Opzelura net sales jumped 28% to $207.3 million in the fourth quarter of 2025, surpassing estimates of $195.6 million and underscoring strong commercial traction in dermatology (Reuters)
Despite raising full-year net sales guidance to $5.13–5.26 billion, the midpoint of $5.20 billion remains well below analysts’ $5.72 billion consensus, highlighting potential revenue shortfall risk (Investing.com)
Multiple generic manufacturers have filed ANDAs challenging patents on ruxolitinib with composition‐of‐matter protections expiring in June 2028 (with pediatric extension) and December 2028 (with pediatric extension), posing a threat to Jakafi’s market exclusivity (SEC 10-Q)
The company flagged an expected $1.27 billion in in-process R&D expense for the third quarter related to the Vega Therapeutics acquisition, which may weigh on near-term profitability and cash flow (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Incyte Financial Performance
Revenues and expenses
Incyte Earnings Performance
Company profitability
Upcoming events
No upcoming events
Incyte News
AllArticlesVideos
Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
Business Wire1 month ago
Incyte Sales Growth Drives Share Price Gains
FXEmpire1 month ago
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 month ago
Funds containing Incyte
AllUSDGBPEUR
Fund name | Fund size | $INCY weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.65% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.65% |
iShares Ageing Population€AGED | €822M | 0.56% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.49% |
iShares Edge MSCI World Minimum Volatility$MVOL | $2.6B | 0.45% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.